A Phase I Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer
K
Kathy Miller, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
The main goal of this study is to determine if GRN163L can be safely given with trastuzumab.
Description
The main goal of this study is to determine if GRN163L can be safely given with trastuzumab.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Breast Cancer
-
Age: Between 18 Years - 100 Years
-
Gender: All
Updated on
19 Apr 2024.
Study ID: 1105005403 (1010-05)
